APGE VS MD Stock Comparison

PerformanceEarningsVolatilityAnalyst Price TargetsSentimentTechnicalsProfit
PerformanceEarningsVolatilityAnalyst Price TargetsSentimentTechnicalsProfit

Performance

APGE
28/100

APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.

MD
10/100

MD returned -39.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

APGE
100/100

APGE has missed earnings 1 times in the last 20 quarters.

MD
10/100

MD has missed earnings 7 times in the last 20 quarters.

Volatility

APGE
44/100

APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

MD
41/100

MD has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Analyst Price Targets

APGE

"Analyst Price Targets" not found for APGE

MD
57/100

14 analysts offer 12-month price targets for MD. Together, they have an average target of 24.67, the most optimistic target put MD at 27 within 12-months and the most pessimistic has MD at 23.

Sentiment

APGE

"Sentiment" not found for APGE

MD
0/100

MD had a bearish sentiment score of 0.00% across Twitter and StockTwits over the last 12 months. It had an average of 0.00 posts, 0.00 comments, and 0.00 likes per day.

Technicals

APGE

"Technicals" not found for APGE

MD
25/100

MD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Profit

APGE

"Profit" not found for APGE

MD
58/100

Out of the last 20 quarters, MD has had 16 profitable quarters and has increased their profits year over year on 6 of them.

All score calculations are broken down here to help you make more informed investing decisions

Apogee Therapeutics, Inc. Common Stock Summary

Nasdaq / APGE
Healthcare
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Pediatrix Medical Group, Inc. Summary

New York Stock Exchange / MD
Healthcare
Medical - Care Facilities
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.